fulvestrant has been researched along with pevonedistat in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; He, S; Hu, X; Jeong, LS; Jia, L; Jia, X; Li, C; Li, L; Liu, G; Liu, X; Lu, Y; Ni, S; Shao, ZM; Sun, H; Yu, J; Yu, K; Zhang, J; Zhang, W; Zhang, Y; Zhao, H; Zhou, L | 1 |
1 other study(ies) available for fulvestrant and pevonedistat
| Article | Year |
|---|---|
Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Forkhead Box Protein O3; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NEDD8 Protein; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2019 |